Welcome to our dedicated page for Firefly Neuroscience SEC filings (Ticker: AIFF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Firefly Neuroscience, Inc. (NASDAQ: AIFF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed technology issuer, Firefly submits annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy materials on Schedule 14A that describe its business, financial condition, governance, and capital structure.
For an AI company focused on EEG- and ERP-based brain analytics software, filings such as the Form 10-K and Form 10-Q detail Firefly’s BNA™ platform, its concentration in the Software – Application industry, its revenue sources in North America, and risk factors related to product development, regulatory matters, and commercialization. Current reports on Form 8-K, including those describing annual meeting results and changes to authorized share capital, provide timely information on material events, shareholder votes, and corporate actions.
Definitive proxy statements (DEF 14A) offer insight into Firefly’s governance practices, director elections, equity incentive plans, and proposals to amend its certificate of incorporation or long-term incentive plan share limits. These documents explain how the board oversees the company’s AI-driven brain health strategy and how equity awards are structured for directors, executives, and employees.
On Stock Titan, each new Firefly filing is captured as it becomes available from EDGAR. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as segment descriptions, updates related to the FDA-cleared BNA™ technology, changes in authorized shares, and outcomes of shareholder meetings. Users can also review ownership and governance information, and locate Form 4 insider transaction reports when they are filed, to see how officers and directors transact in AIFF stock. This page is a centralized resource for investors who want to understand Firefly’s regulatory history and the formal disclosures that support analysis of its AI-based brain analytics business.
Firefly Neuroscience (AIFF) filed a Form 144 notifying the proposed sale of 30,126 shares of common stock, scheduled to be sold on 10/09/2025 on NASDAQ. The filing lists an aggregate market value of $86,694.86 for the shares and shows 13,448,848 shares outstanding, making the block roughly 0.224% of the outstanding stock. The securities were acquired on 08/12/2024 as merger consideration, with 1,636,990 shares received in that transaction. No securities were reported sold by the same person in the past three months. The filer certifies they are not aware of undisclosed material adverse information.
Firefly Neuroscience, Inc. (AIFF) is soliciting proxies for its 2025 Annual Meeting to be held virtually at 10:00 a.m. ET on October 27, 2025. The Board recommends votes FOR five proposals: elect two Class II directors (nominees Brian Posner and Stella Vnook), ratify appointment of Marcum as independent auditor for fiscal 2025, approve an amendment to the equity incentive plan to add 317,820 shares and an annual automatic increase (lower of 4% of outstanding common stock or Board-determined amount) from January 1, 2026 through January 1, 2035, authorize the Board to increase authorized shares up to an aggregate of 5,001,000,000 (including 1,000,000 preferred shares), and allow adjournment if needed to solicit additional proxies. Materials including the 2024 Form 10-K are available at www.proxyvote.com and the virtual meeting website. The proxy describes Board composition, committee charters, indemnification and director compensation (option awards for non-employee directors), and discloses pay-versus-performance information noting that net loss increased from 2023 to 2024 while compensation actually paid (CAP) to NEOs increased. Voting methods (Internet, mail, virtual) and quorum/broker-vote rules are explained.
Firefly Neuroscience, Inc. has issued a preliminary proxy for its virtual 2025 Annual Meeting to be held October 31, 2025. The Board recommends five proposals: elect two Class II directors to three-year terms ending 2028; ratify Marcum as independent auditor for fiscal 2025; approve Amendment No. 1 to the equity incentive plan to add 317,820 shares and provide annual automatic increases (up to 4% of outstanding shares) from January 1, 2026 through January 1, 2035; authorize the Board to increase authorized shares from 101,000,000 to up to 5,001,000,000 (including 1,000,000 preferred); and permit adjournment if needed to solicit votes. The proxy discloses board composition, committee charters, related-person transaction review procedures, indemnification and insurance, and executive compensation summary including pay-versus-performance tables and narrative. Proxy materials and the 2024 Form 10-K are available at the links provided.